Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition

被引:0
作者
Maura Dandri
Antonio Bertoletti
Marc Lütgehetmann
机构
[1] University Medical Center Hamburg-Eppendorf,I. Department of Internal Medicine, Center for Internal Medicine
[2] German Center for Infection Research (DZIF),Hamburg
[3] Agency of Science Technology and Research (ASTAR),Lübeck
[4] Duke-NUS Medical School,Borstel
[5] University Medical Center Hamburg-Eppendorf,Riems partner site
来源
Seminars in Immunopathology | 2021年 / 43卷
关键词
Hepatitis B virus; Hepatitis D virus; Innate immunity; Hepatocytes;
D O I
暂无
中图分类号
学科分类号
摘要
Chronic infections with human hepatitis viruses continue to be a major health burden worldwide. Despite the availability of an effective prophylactic vaccine against the hepatitis B virus (HBV) and of antiviral agents efficiently suppressing HBV replication, more than 250 million people are currently chronically infected with this hepatotropic DNA virus, and resolution of chronic hepatitis B (CHB) is rarely achieved. Moreover, coinfection with the hepatitis D virus (HDV), a human RNA satellite virus requiring the envelope proteins of HBV for productive viral spreading, substantially aggravates the disease course of CHB. The molecular mechanisms by which these viruses interact with each other and with the intrinsic innate responses of the hepatocytes are not fully understood. While HBV appears to avoid innate immune recognition, HDV elicits a strong enhancement of innate responses. Notwithstanding, such induction does not hamper HDV replication but contributes to liver inflammation and pathogenesis. Intriguingly, HDV appears to influence the ability of T cells to recognize infected hepatocytes by boosting antigen presentation. This review focuses on current knowledge regarding how these viruses can shape and counteract the intrinsic innate responses of the hepatocytes, thus affecting the immune system and pathogenesis. Understanding the distinct strategies of persistence that HBV and HDV have evolved is central for advancing the development of curative therapies.
引用
收藏
页码:535 / 548
页数:13
相关论文
共 899 条
  • [1] Revill PA(2019)A global scientific strategy to cure hepatitis B Lancet Gastroenterol Hepatol 4 545-558
  • [2] Chisari FV(2019)Global elimination of chronic hepatitis N Engl J Med 380 2041-2050
  • [3] Block JM(2020)cccDNA maintenance in chronic hepatitis B - targeting the matrix of viral replication Infect Drug Resist 13 3873-3886
  • [4] Dandri M(2018)Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance Hepatology 67 1560-1599
  • [5] Gehring AJ(2019)Therapeutic strategies for hepatitis B virus infection: towards a cure Nat Rev Drug Discov 18 827-844
  • [6] Guo H(2012)Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection Gut 61 1754-1764
  • [7] Hu J(2012)Chronic hepatitis B in children and adolescents J Hepatol 57 885-896
  • [8] Kramvis A(2001)Noncytolytic control of viral infections by the innate and adaptive immune response Annu Rev Immunol 19 65-91
  • [9] Lampertico P(2016)Adaptive immunity in HBV infection J Hepatol 64 S71-S83
  • [10] Janssen HLA(2012)Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B Gastroenterology 143 637-645